Baloxavir Marboxil for Influenza Prophylaxis

Guideline Recommendations

• The American Academy of Pediatrics does not specifically recommend baloxavir marboxil for routine postexposure prophylaxis in their 2024 guidelines, instead focusing on oseltamivir and zanamivir for prophylaxis 1, 2
• Postexposure chemoprophylaxis is recommended for high-risk individuals, particularly those unvaccinated, recently vaccinated, or immunocompromised, according to the American Academy of Pediatrics 1, 2

Administration and Safety

• The American Academy of Pediatrics recommends avoiding administration of baloxavir with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements, as these significantly reduce antiviral efficacy 1, 2
• Baloxavir is not recommended for pregnant or breastfeeding women, according to the American Academy of Pediatrics 1, 2
• The American Academy of Pediatrics advises against using baloxavir as monotherapy in severely immunocompromised patients due to concerns about resistance emergence 1, 2

Alternative Prophylactic Agents

• Oseltamivir remains a recommended prophylactic agent with extensive guideline support, requiring 75 mg once daily for 10 days in adults, as suggested by the Centers for Disease Control and Prevention, although the exact citation is from Praxis Medical Insights, an alternative source is preferred but not available 6